Related Experiment Videos
The development of busulfan/cyclophosphamide preparative regimens
1Bone Marrow Transplantation Program, Johns Hopkins Oncology Center, Baltimore, MD 21287.
Seminars in Oncology
|August 1, 1993
Summary
Busulfan (Bu) and cyclophosphamide (Cy) combination chemotherapy is an effective bone marrow transplantation (BMT) preparative regimen. This BuCy regimen eradicates host marrow and suppresses immunity, enabling successful engraftment for various conditions.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Busulfan (Bu) and cyclophosphamide (Cy) were developed as bone marrow transplantation (BMT) preparative regimens, offering an alternative to total body irradiation (TBI).
- Bu exhibits potent myeloablative and antileukemic activity but limited immunosuppression.
- Cy provides sufficient immunosuppression for allogeneic marrow engraftment.
Purpose of the Study:
- To evaluate the efficacy of busulfan and cyclophosphamide (BuCy) as a bone marrow transplantation preparative regimen.
- To compare BuCy regimens with those utilizing total body irradiation (TBI) and cyclophosphamide (TBI/Cy).
Main Methods:
- Development and application of BuCy preparative regimens for BMT.
- Assessment of myeloablative, antileukemic, and immunosuppressive effects in animal and human studies.
- Comparison of BuCy regimens with TBI/Cy regimens in leukemic patients.
Main Results:
- The BuCy combination effectively eradicates host bone marrow and suppresses the immune response in both animals and humans.
- This allows for successful engraftment of allogeneic or autologous marrow.
- BuCy regimens demonstrate comparable efficacy to TBI/Cy regimens, with few comparative studies available.
Conclusions:
- BuCy preparative regimens are effective for BMT in leukemic patients.
- These regimens are also utilized for nonmalignant lymphohematopoietic disorders and other malignant diseases.
- BuCy offers a viable alternative to TBI-based preparative regimens for BMT.